New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance

scientific article published on 20 September 2018

New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1080/10428194.2018.1488253
P698PubMed publication ID30234404

P50authorBarbara EichhorstQ47158788
Stephan StilgenbauerQ47158807
Jasmin BahloQ108428543
P2093author name stringKarl-Anton Kreuzer
Michael Hallek
Marco Herling
Georg Hopfinger
Thorsten Zenz
Alexandra Schrader
Petra Mayer
Anna-Maria Fink
Natali Pflug
Paula Cramer
Anne Westermann
Jan Dürig
Till Seiler
Sandra Robrecht
Sebastian Oberbeck
P433issue3
P921main subjectlessons learnedQ1673259
phase II clinical trialQ42824440
P304page(s)649-657
P577publication date2018-09-20
P1433published inLeukemia & LymphomaQ6534493
P1476titleNew lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance
P478volume60

Reverse relations

cites work (P2860)
Q89604787Advances and Perspectives in the Treatment of T-PLL
Q89882463Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine
Q61813698The dawn of a new era in treating T-PLL

Search more.